Shallis, Rory M.
Zeidan, Amer M. http://orcid.org/0000-0002-8542-2944
Article History
Accepted: 11 June 2021
First Online: 3 August 2021
Declarations
:
: No external funding was used in the preparation of this article.
: Amer M. Zeidan received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene/Cardiff oncology, Incyte, Takeda, Novartis, Amgen, Aprea, and ADC Therapeutics. Amer M. Zeidan participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Aprea, Janssen, Lox Oncology, Genentech, Servier, Jasper, and Tyme. Amer M. Zeidan served on clinical trial committees for Novartis, Abbvie, Geron, Gilead, Kura, Lox Oncology, BioCryst, and Celgene/BMS. Amer M. Zeidan received travel support for meetings from Pfizer, Novartis, and Cardiff Oncology. Rory M. Shallis owned stock in Curis.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Rory M. Shallis and Amer M. Zeidan conceptualized and wrote the manuscript.